Hospital

Biological sex and societal gender factors independently—and differently—influence TBI mortality, discharge destination, and long-term cognitive recovery.

Despite the availability of 4 FDA-approved biologics, the majority of NMOSD patients remain on off-label rituximab.

Sex and gender differences remain critically underrepresented in traumatic brain injury clinical guidelines.

There is an increasing interest in de-escalation strategies for HER2-positive breast cancer aimed at decreasing toxicity exposure while maintaining efficacy.

Amber Clemmons PharmD, BCOP, FHOPA, highlights key changes in evidence grading, shared decision-making, and dosing strategies in neutropenia management.

McCreary and Dudley emphasize the role of pharmacists when optimizing antimicrobial use, supporting patient care across diverse settings, and driving education, research, and policy.

Gwen Nichols shares her dream of changing the landscape of pediatric cancer research and care.

Cone Health Cancer Center pharmacists lead bispecific T-cell engager rollout, boosting local access to care.

Experts describe how infectious disease pharmacists drive antimicrobial stewardship, tackle resistance, and shape global training as SIDP marks 35 years.

When performed appropriately, medication reconciliations can reduce discrepancies from as high as 70% to as low as 15%.

Pharmacist lung cancer insights on NSCLC: biomarker testing, PD-1 choices like cemiplimab, and access tips for treating non small cell lung cancer.

COVID-19 infection may create lasting changes in the lung microenvironment—particularly through thymidine phosphorylase–driven pathways—that could increase the risk of lung cancer over time.

Anthony Blaszczyk, PhD, explains the intricacy of CGT manufacturing demands, best practices, and how USP is supporting developers.

This decision builds upon the drug’s initial approval for adult patients and introduces a new therapeutic option for clinicians treating pediatric populations with rapid heart rate disturbances.

WHI data link radon exposure to higher ovarian cancer risk and deaths; learn how home testing may reduce cancer risk in high-radon areas.

Beyond memantine's approved use in Alzheimer disease, emerging evidence highlights a possible role for it in select epilepsy cases.

The indication is to reduce proteinuria in adults and children aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic symptoms.

Emerging therapeutic options represent a new age for treatment of high-risk non–muscle invasive bladder cancer.

FDA fast track designation advances oral EP300/CBP inhibitor OPN-6602 for relapsed/refractory multiple myeloma, highlighting novel hematology-oncology options and key pharmacist considerations.

Students should consider reaching out to their experiential education department to learn what opportunities may be available.

Real-world data show pharmacist-driven obesity care models may offer greater improvements in hemoglobin A1C and lipid parameters while supporting multidisciplinary, patient-centered care.

PCOS in female athletes often goes unrecognized due to atypical presentations, requiring careful differentiation, individualized management, and a multidisciplinary approach to protect both performance and long-term health.

New evidence shows that human papillomavirus (HPV) 9-valent vaccine protection lasts up to 14 years. Learn why early vaccination and pharmacists can boost cancer prevention.

Cristian Tomasetti, PhD, explains how obesity enlarges organs, raising cancer risk, and how GLP-1 weight loss therapy may reverse this, guiding oncology pharmacists.

Early immune signals can program longer-lasting lung-resident T cells—a potential breakthrough for influenza and COVID-19 vaccine design.

LIV Process is a patented, water-based solution that allows hospitals and long-term care facilities to see live C difficile spores on surfaces in 2 minutes.

In AML, sialylated CD43 blocks immune clearance beyond CD47, revealing new leukemia targets to boost macrophage phagocytosis.